Aspen Neuroscience, a clinical‑stage biotechnology company has appointed Revati Shreeniwas as Chief Medical Officer (CMO) to help accelerate late‑stage development and commercial readiness for its cell therapy for Parkinson’s disease.
Shreeniwas’ appointment is part of leadership changes designed to move programs from the clinic to the market with integrity and purpose, San Diego, California-based company pioneering autologous regenerative therapies, announced.
Dr. Shreeniwas, who received her medical education from Armed Forces Medical College in Pune, India, has deep expertise in neuromuscular and CNS diseases; orphan indications; cardiovascular and respiratory diseases; and gene therapy.
As a board-certified physician executive with over 20 years of experience leading global clinical development in the biopharma industry—including multiple roles as Chief Medical Officer, she has a proven track record of advancing programs from pre-IND through to registration, successfully navigating global regulatory pathways, and shaping clinical and medical strategy for venture‑backed companies.
READ: Indian American physician pleads guilty to federal drug crimes (July 15, 2025)
She has designed and led more than 40 global clinical trials, including registrational studies, and contributed to the approval and commercialization of Rytary (Parkinson’s), Sunosi (sleep disorders), Esbriet (IPF), and Tracleer (pulmonary hypertension).
“Aspen’s autologous iPSC‑derived approach is redefining what’s possible in neurodegenerative disease. I’m excited to help deliver a rigorous registrational program for Parkinson’s patients, partnering across clinical, regulatory, technical operations, and medical affairs,” said Shreeniwas.
Prior to Aspen, Dr. Shreeniwas served in senior clinical roles at Cystetic Medicines, Excision BioTherapeutics, Bright Minds Biosciences, and Soleno Therapeutics, among others.
Dr. Shreeniwas has held faculty appointments at Columbia University and Stanford University before working in the biopharma industry.
Aspen’s ANPD001 is the most advanced autologous investigational cell therapy in the United States for treating Parkinson’s disease, according to a company release.
Aspen’s personalized approach means that patients do not require immunosuppressive (IS) drugs to dampen the body’s immune response against foreign cells. This approach will eliminate IS-associated adverse events, IS drug-monitoring requirements, and enable dosing for those with contraindications to IS therapies, Aspen stated.
ANPD001 has received Fast Track designation by the U.S. Food and Drug Administration (FDA).
ASPIRO is the first multi-patient, multi-center clinical trial of an autologous cell therapy for Parkinson’s disease. It is evaluating safety, tolerability, and preliminary efficacy of ANPD001 in levodopa-responsive patients aged 50–70. Primary endpoints will be reported at 12 months, with long-term follow-up extending to 15 years.
1 Comment
My husband gained about 60 lbs. he ended up having PD-5 formula, which I know isn’t recommended in this group. It was his choice. He has lost 50 lbs since July . His high was 300. he also had terrible sleep patterns even before his dx.he now sleep all night with PD-5 formula from limitless healthcenter . Co m well wishes